Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
68 /100
COMPONENT-LIMITED
Score updated Sep 12, 2026

INKT — MiNK Therapeutics, Inc. Dilution Risk Tracker

Track INKT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track INKT — Get alerts when the score changes →

As of September 12, 2026, MiNK Therapeutics, Inc. (INKT) has a DilutionWatch DilutionScore of 68/100, rated HIGH dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. MiNK Therapeutics, Inc. has a market capitalization of $60.78M, 5.10M shares outstanding, 1 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
65
📊 Float Risk
80
⚠️ Warrant Exposure
40
🔄 Convertible Debt
85

Dilution Forecast

⛈️
Warning
High probability of dilution event
model est. 36%
🔁 Convertible Conversion model 60%
• Major convertible overhang: 72% potential dilution
• Convertible risk score very high (85/100)
💰 Capital Raise model 15%
• Under 12 months cash (11mo)
📉 Score Deterioration model 10%
• Score in HIGH risk zone (68/100)
🔔 Track INKT — Get forecast alerts →

Market Data

Market Cap$60.78M
Shares Outstanding5.10M
Float1.96M
Cash$8.81M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore68/100DilutionWatch score record
Shares Outstanding5.10MVerified float table or market cache
Public Float1.96MVerified float table or market cache
Market Cap$60.78MMarket data cache
Cash Runway10.6 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 416.1% shares (2025Q4 vs prior)
1 institutional holders · 160 shares
#1 HORIZON FINANCIAL SERVICES, LLC 160 shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest65.0K
Days to Cover6.8
% of Float3.3%
FINRA data as of Aug 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2021-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual INKT Dilution Snapshot

MiNK Therapeutics, Inc. (INKT) has a DilutionScore of 68/100, rated High dilution risk. Score date: September 12, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track INKT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking INKT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,348+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for INKT
INKT FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.